ChemoCentryx reported a decrease in revenue due to new accounting standards and a net loss, which may concern investors in the short term. However, the strong cash position and ongoing progress in multiple clinical trials provide confidence in the company's future prospects. Overall, these mixed signals are likely to result in a neutral short-term impact on the stock price.

[0]